| Catalog No. | AV974014 |
|---|
| Applications | ELISA |
|---|
| Host species | Rabbit |
|---|
| Isotype | IgG |
|---|
| Clonality |
Polyclonal |
| Immunogen |
Durvalumab |
| Target |
Rabbit polyclonal antibody to Imfinzi. |
| Specificity |
The product is specific for Durvalumab. This antibody serves as an excellent positive control for Durvalumab immunogenicity (ADA) assays. |
| Endotoxin level |
Please contact with the lab for this information. |
| Purification |
Purified by antigen affinity column. |
| Accession |
CAS: 1428935-60-7 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| Product Usage Information |
| Application |
Dilution |
| ELISA |
1:5000-1:20000 |
| IHC |
1:50-1:500 |
| WB |
1:500-1:2000 |
|
|---|
| Stability and Storage |
The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles. |
| Background | Durvalumab (Imfinzi) is a human IgG1 monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of cancer. It was developed by Medimmune/AstraZeneca. Durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody which blocks the interaction of PD-L1 with the PD-1 and CD80 molecules.Antibodysystem Anti-Durvalumab Antibody, pAb, Rabbit is produced from sera of a rabbit immunized with Durvalumab.
|
|---|
| Note |
For research use only. |
中文
English
